John D. Vandermosten, CFA

John D. Vandermosten, CFA

About
John D. Vandermosten, CFA is a senior biotechnology research analyst for Zacks SCR where he covers a portfolio of small cap equities. He has 20 years of experience in a variety of investment management and research roles across all market cap ranges ...
A Tale of Tangles Chapter Three: The Desert Expanse
Source: © Sergey Pesterev / Wikimedia Commons / CC BY-SA 4.0 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Partner Content
What's Behind Alzheimer's Disease?
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Partner Content
A Tale Of Tangles We Weave
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.  
Partner Content
Aduhelm: Catalyst for a Sentiment Shift
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Partner Content
More Specificity is What the Doctor Ordered
Photo by Steven HWG on Unsplash
Partner Content
New Alternatives for Branded Biologics
We’ve all heard about generic drugs. They are time-tested and battle-proven medicines that are more affordable than their patented predecessors. Branded drugs consistently break new records for high treatment costs, while overall drug prices have increased faster than inflation for decades.
Partner Content

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved